TAG Vice President Sam Ide Comments on Recent BIOSECURE Act and Its Impact on the Biotech Sector and U.S. Companies Partnered With Chinese Firms
“WuXi’s alleged ties are a much newer focus of Congress, compared to BGI’s,” said Sam Ide, a VP at Asia Group’s China practice, where he advises clients on navigating policy.